Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Oktober 2018 06:00 ET | Quelle: Mesoblast Limited

Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China

NEW YORK and MELBOURNE, Australia, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to...
02. Oktober 2018 06:00 ET | Quelle: Mesoblast Limited

Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions

NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial...
25. September 2018 06:01 ET | Quelle: Mesoblast Limited

Mesoblast Heart Failure Cell Therapy for Children Featured at Regenerative Symposium for Congenital Heart Disease

NEW YORK and MELBOURNE, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB, Nasdaq:MESO) today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell...
20. September 2018 06:30 ET | Quelle: Mesoblast Limited

Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblast’s Phase 3 Trial for Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced continued strong survival outcomes through Day 180 in children with...
17. September 2018 06:00 ET | Quelle: Mesoblast Limited

Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast

NEW YORK and MELBOURNE, Australia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has successfully obtained all...
17. Juli 2018 06:32 ET | Quelle: Mesoblast Limited

Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group

NEW YORK and MELBOURNE, Australia, July 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a strategic alliance with one of China’s...
11. Juli 2018 06:00 ET | Quelle: Mesoblast Limited

Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board

NEW YORK and MELBOURNE, Australia, July 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Shawn Cline Tomasello has joined its Board of Directors. With more...
02. Juli 2018 06:00 ET | Quelle: Mesoblast Limited

Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced a US$50 million financing from NovaQuest Capital Management, L.L.C....
21. Juni 2018 06:00 ET | Quelle: Mesoblast Limited

Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting

NEW YORK and MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L,...
19. Juni 2018 06:00 ET | Quelle: Mesoblast Limited

U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board

NEW YORK and MELBOURNE, Australia, June 19, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish...

Vorherige Seite